home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2815.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
49 lines
Document 2815
DOCN M94A2815
TI Lymphoproliferative responses in HIV-1-seropositive volunteers pre and
post immunization with immuno rgp160. European Multinational Immuno AIDS
Vaccine Study Group.
DT 9412
AU Mannhalter JW; Eibl MM; Wahren B; Blazevic V; Goebel FD
SO Int Conf AIDS. 1994 Aug 7-12;10(1):219 (abstract no. PB0305). Unique
Identifier : AIDSLINE ICA10/94369760
AB OBJECTIVE: To evaluate antigen- and mitogen-induced lymphoproliferative
responses in two groups of HIV-1-seropositive volunteers (randomized
according to different CD4 strata: CD4 counts > 500 and CD4 counts from
200 to 500) pre and post immunization with the IMMUNO rgp160 AIDS
candidate vaccine. METHODS: In a double-blind, placebo-controlled phase
I/II study, vaccinees got 6 monthly intramuscular injections of either
the AIDS candidate vaccine (containing 100 ug rgp160 IIIB per dose) or
placebo (adjuvant only). One half of the volunteers received the
vaccine, the other half placebo. At various time points pre and post
immunization, lymphoproliferative responses to antigens (HIV-1 envelope
proteins, tetanus toxoid, CMV antigen, alloantigens) and mitogens (PWM,
PHA) were assessed. RESULTS: Prior to immunization with the AIDS
candidate vaccine, rgp160-induced lymphocyte proliferation was absent or
very low in all HIV-1-seropositive volunteers. Responses to recall
antigens and mitogens were observed in both groups of volunteers, but
were lower in magnitude than in HIV-1-seronegative controls.
Proliferation in response to alloantigens was comparable in
HIV-1-seropositive and HIV-1-seronegative subjects. Post immunization
with the rgp160 vaccine, HIV-1 envelope-specific lymphoproliferative
responses were found in one half of the volunteers with CD4 > 500 and in
one third of the subjects with CD4 between 200 and 500 (note that only
half of the volunteers received the vaccine). CONCLUSIONS: The IMMUNO
AIDS candidate vaccine induces HIV-1 env-specific T cell memory in
HIV-1-seropositives with CD4-pos. T cells > 500 and CD4-pos. T cells
between 200 and 500.
DE Antigens/IMMUNOLOGY AIDS Vaccines/*THERAPEUTIC USE Gene Products,
env/PHARMACOLOGY/*THERAPEUTIC USE Human HIV
Infections/IMMUNOLOGY/*THERAPY HIV-1/*IMMUNOLOGY Immunization
Immunologic Memory *Immunotherapy, Active *Lymphocyte
Transformation/DRUG EFFECTS Mitogens/PHARMACOLOGY Protein
Precursors/PHARMACOLOGY/*THERAPEUTIC USE Recombinant
Proteins/PHARMACOLOGY/THERAPEUTIC USE T-Lymphocyte Subsets/IMMUNOLOGY
Vaccines, Synthetic/THERAPEUTIC USE CLINICAL TRIAL CLINICAL TRIAL,
PHASE I CLINICAL TRIAL, PHASE II MEETING ABSTRACT RANDOMIZED
CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).